Several studies have shown that GRHL2 showed a different degree of expression in a wide variety of tumor tissues, including epithelial squamous cell cancer, breast carcinoma, gastrointestinal cancer, liver cell cancer, colon cancer, renal carcinoma, cervical cancer, neuroblastoma, and prostate cancer. Here, GRHL2 is linked to neuroblastoma.